



3D Control

Voglibose

Metformin


Glimepiride

LAFORMIN

GV-1 / GV-2

Glimepiride, Voglibose & Metformin ER Tablets
(1 mg + 0.2 mg + 500 mg/2 mg+0.2 mg + 500 mg)

Triple drug therapy in the management of type 2 Diabetes Mellitus



Reference: Endocrine practice. May/June 2013; 19; suppl 2: 1-48

Poor Adherence to treatment of Type 2 Diabetes Mellitus Patients

“Drugs don't work in patients who don't take them”

- A study of 600 type 2 diabetes patients.
- Only 16.6% patients were adherent to prescribed anti-diabetic drugs.
- Non-adherence was highly significantly ($p < 0.001$) associated with frequent dosing and multiple drugs.¹
- More than half of patients desired less number frequency of medications.¹

Fixed-dose combination decreases the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension for improving medication compliance which can translate into better clinical outcomes.²

Reference:

1. JIACM 2014; 15(1): 26-9

2. Am J Med. 2007 Aug;120(8):713-9

LAFORMIN-GV-1/GV-2

Glimepiride, Voglibose & Metformin ER Tablets (1 mg + 0.2 mg + 500 mg/2 mg+0.2 mg + 500 mg)

Fixed Dose Combination for Treatment of Type 2 Diabetes Mellitus

Reduced Pill Burden

- Better Patients adherence to therapy

Increased Adherence

- Better Glycemic control
- Reduced disease management cost

Different Strengths of FDCs

- Dosing flexibility

Reference: Adv Ther 2012; Jan 29 (1): 1-13

Addition of Voglibose to Glimepiride and Metformin have Better Glucose Control in Diabetics

Group A: Glimepiride + Metformin (n=50)

Group B: Voglibose + Glimepiride + Metformin (n=50)

Study Duration: 10 months

	Group B		
	Before Treatment	After Treatment	P-Value
Total Cholesterol (mg/dl)	151.28 ± 5.60	141.28 ± 4.44	0.023
Triglyceride (mg/dl)	132.84 ± 9.35	120.14 ± 5.89	0.043
LDL (mg/dl)	97.52 ± 5.53	88.18 ± 4.47	0.011
HDL(mg/dl)	38.98 ± 1.17	39.38 ± 1.32	0.000

The add-on therapy using voglibose in dual therapy including glimepiride and metformin showed a very significant benefit in controlling the glucose triad levels when compared to dual therapy. Voglibose has an effect to decrease TC, TG and LDL level and increase HDL significantly.

Reference: Int.J.Pharmaco., 12(4): 422-428, 2016

LAFORMIN-GV-1/GV-2

Glimepiride, Voglibose & Metformin ER Tablets (1 mg + 0.2 mg + 500 mg/2 mg+0.2 mg + 500 mg)

Description:

Laformin GV-1 and **GV-2** is a Triple drug Combination consists of Glimepiride, Voglibose and Metformin Extended Release for the treatment and management of type-2 diabetes mellitus in adults.

Indication:

LAFORMIN GV-1/GV-2 is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes who are already treated with a combination of glimepiride and metformin or whose diabetes is not adequately controlled with metformin alone or for those patients who have initially responded to glimepiride alone and require additional glycemic control.

Mechanism of Action:




- **Glimepiride:** The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells.
- **Metformin:** Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
- **Voglibose:** Voglibose is an alpha glucosidase inhibitor which reduces intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α -glucosidase in the intestinal brush border. Inhibition of this enzyme catalyzes the decomposition of disaccharides into monosaccharides and slows the digestion and absorption of carbohydrates; the post-prandial rise in plasma glucose is blunted in both normal and diabetic subjects resulting in improvement of post prandial hyperglycemia and various disorders caused by hyperglycemia.
- Hence, the combination of glimepiride, metformin sustained-release and Voglibose complements each other and provides better glycemic control in management of type-2 diabetes and probably in the prevention of its associated macrovascular and microvascular complications.

Dosage:

LAFORMIN GV-1/GV-2 should be initiated once daily, and gradually titrated after assessing the therapeutic response.

La Renon Healthcare Pvt. Ltd.

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-3046-1000 (30 lines) | Fax: +91-79-3046-1001
E-mail: info@larenon.com | Web: www.larenon.com

	I am: _____
	Call me on: _____
	Mail me at: _____